Tetanus Immune Globulin (TIG)
Treatment for Tetanus
Typical Dosage: 3000-6000 IU IM or IV, depending on severity and formulation
Effectiveness
90%
Safety Score
75%
Clinical Trials
8
Participants
5K
Comparative Safety Scale(Higher is safer)
Cyanideβ οΈ
Methπ
Cigarettesπ¬
Chemoβ’οΈ
AlcoholπΊ
Morphineπ
Antibioticsπ
Tylenolπ
Exerciseπ
Waterπ§
75
DangerousModerateSafe
Treatment Details
Dosage Range
3000-6000 IU IM or IV, depending on severity and formulation
Time to Effect
Immediate (neutralizes unbound toxin)
Treatment Duration
Single dose (sometimes repeated)
Evidence Quality
HIGHNumber Needed to Harm (NNH)
200(Treat 200 patients to see 1 additional serious adverse event)
Confidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$1,500
Monitoring:$50
Side Effect Mgmt:$20
Total Annual:$1,570
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTQALYs Gained
15
Outcome-Based Costs
Cost per Responder
$1,847
Cost per Remission
$2,243
Tetanus Immune Globulin (TIG) Outcomes
for Tetanus
Efficacy Outcomes
Overall Effectiveness
+90%
Response Rate
+85%
Remission Rate
+70%
Common Side Effects
Local pain/tenderness at injection site
+15%
Fever
+5%
Allergic reactions (rash, itching)
+1%
Sources:
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
3 active trials recruiting for Tetanus Immune Globulin (TIG) in Tetanus
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Anti-Tetanus Toxin Monoclonal Antibody Injection
NCT07149454ENROLLING BY INVITATIONPHASE1
68 participants
INTERVENTIONAL
Lanzhou, China
Started: Aug 18, 2025
A Phase III Clinical Trail to Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity Characteristics of GR2001 Injection
NCT06635798RECRUITINGPHASE3
582 participants
INTERVENTIONAL
Hefei, China +19 more
Started: Sep 3, 2024
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SNA02-48 Injection in Chinese Adult Participants
NCT06939777NOT YET RECRUITINGPHASE1, PHASE2
255 participants
INTERVENTIONAL
Hefei, China
Started: Apr 1, 2025
Completed Clinical Trials
4 completed trials for Tetanus Immune Globulin (TIG) in Tetanus
The Change of the Tetanus Antibody Titer After Single Injection of Td and Simultaneous Injection of TIG With Td
NCT01338688COMPLETED
250 participants
OBSERVATIONAL
Started: Oct 1, 2008
Study to Compare the Efficacy and Safety of Passive Immunization With TNM002 Injection and Human Tetanus Immunoglobulin as Prophylaxis Against Tetanus
NCT05664750COMPLETEDPHASE3
675 participants
INTERVENTIONAL
Hefei, China +27 more
Started: Dec 22, 2022
Intrathecal Tetanus Immunoglobulin to Treat Tetanus
NCT02999815COMPLETEDPHASE1, PHASE2
272 participants
INTERVENTIONAL
Ho Chi Minh City, Vietnam
Started: Feb 13, 2017
Study to Compare the Anti-tetanus Neutralizing Antibody Titers and Safety of TNM002 Injection With Human Tetanus Immunoglobulin or Placebo in Adult Volunteers
NCT05625477COMPLETEDPHASE2
240 participants
INTERVENTIONAL
Shantou, China +3 more
Started: Apr 18, 2022